ScholarX: PARK, WON

Detailed Information

PARK, WON (박원)

Medicine (Medicine)

Research Area

Tel 02-3410-2616
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Radiotherapy:61||Breast cancer:29||Breast neoplasms:28||Radiation therapy:19||radiotherapy:17||Adjuvant radiotherapy:12||Mastectomy:9||breast cancer:9||Recurrence:9||cervical cancer:8||Breast neoplasm:8||Uterine cervical neoplasms:8||Prognosis:8||Rectal neoplasms:7||Cervical cancer:7||Prostate cancer:7||Korea:7||Adjuvant chemoradiotherapy:6||Neoadjuvant chemotherapy:6||Neoadjuvant therapy:6||Magnetic resonance imaging:6||Lymph nodes:5||Survival:5||Concurrent chemoradiotherapy:5||Prostatic neoplasms:5||Neoadjuvant chemoradiotherapy:4||Rectal cancer:4||Adenocarcinoma:4||BRCA1:4||Cervical Cancer:4||BRCA2:4||radiation therapy:4||Proton beam therapy:4||Risk factors:4||Ductal carcinoma in situ:4||Treatment outcome:4||prostate cancer:4||HER2:4||postmastectomy radiotherapy:3||Local neoplasm recurrence:3||Local excision:3||Prostatespecific antigen:3||Diseasefree survival:3||Prostatectomy:3||BRCA mutation:3||Proton therapy:3||Uterine cervical cancer:3||MRI:3||Chemoradiotherapy:3||Salvage radiotherapy:3||Chemotherapy:3||Breast:3||Adjuvant therapy:3||Taxane:3||Hysterectomy:3||prognosis:3||Treatment planning:3||Angiotensin converting enzyme inhibitors:2||Endometrial cancer:2||Circulating tumor DNA:2||Radiation effects:2||Radiation injuries:2||Clinical target volume:2||IMRT:2||Radiodermatitis:2||Lymphatic irradiation:2||Optimization:2||chemotherapy:2||Breast reconstruction:2||concurrent chemoradiotherapy:2||Rectal volume:2||deep learning:2||Complete remission:2||Magnetic resonance image:2||Extramammary Paget disease:2||Adjuvant treatment:2||Mammoplasty:2||Internal mammalian lymph node:2||Adverse events:2||Risk factor:2||CD24:2||Internal mammary node:2||hypofractionation:2||Adenoid cystic carcinoma:2||Segmental mastectomy:2||Patterns of care:2||Sequence:2||Interobserver variation:2||Metastasis:2||Deep learning:2||Japan:2||Boost:2||lymph nodes:2||Subtype:2||Postmastectomy radiation therapy:2||Brachytherapy:2||Bragg peak:2||Surgery:2||Casecontrol study:2||Brain metastases:2||Survival analysis:2||Preoperative chemoradiotherapy:2||Target volume:2||Leukopenia:2||Trastuzumab:2||practice patterns:2||Prognostic factor:2||Triple negative breast neoplasms:2||Tumor regression grade:2||rectal neoplasm:2||recurrence:2||Urinary bladder neoplasms:2||risk factors:2||Local recurrence:2||Uterine cervical neoplasm:2||survival:2||Neoplasm metastasis:2||Quality of life:2||triplenegative breast cancer:2||Locoregional recurrence:2||Hereditary breast and ovarian cancer syndrome:2||Neutrophil:2||Internal mammary lymph nodes:1||Internal mammary node irradiation:1||Invasive ductal carcinoma:1||Invasive micropapillary carcinoma:1||Keywords: Breast neoplasms:1||Keywords: Proton therapy:1||Keywords: Radiotherapy:1||Knee:1||Korean:1||Lamina propria:1||Laparoscopy:1||Lateral lymph node:1||Lateral pelvic recurrence:1||Leftsided breast neoplasms:1||Leptomeningeal metastases:1||Liver:1||Lobular carcinoma:1||Local:1||Local control:1||Local therapy:1||Locoregional progression:1||Locoregional control:1||Logistic regression:1||Lumpectomy:1||Lymph node ratio:1||Lymphnode ratio:1||Lymphadenectomy:1||Lymphatic:1||Lymphatic Metastasis:1||Lymphatic irradiations:1||Lymphatic metastasis:1||Lymphedema:1||Lymphoma:1||Machine learning:1||Major complication:1||Malignant phyllodes tumor:1||Malignant transformation:1||Mammaplasty:1||Manganese porphyrin:1||Margin:1||Margins of excision:1||Measurement:1||Metachronous Neoplasm:1||Metaplastic breast cancer:1||Metastatic breast cancer:1||Metastatic colorectal cancer:1||Mn porphyrin clinical candidate:1||MnBuOE):1||MnTnBuOE2PyP<sup>5+</sup> (BMX001:1||MnTnHex2PyP:1||MnTnHex2PyP5+:1||Monte Carlo dose calculation:1||Multimodality:1||Multivariate analysis:1||Muscleinvasive:1||Myotonometer:1||N1:1||N3:1||NBS1:1||NCCN:1||NRF2:1||Nasopharyngeal Neoplasms:1||National health insurance:1||Neoadjuvant:1||Neoadjuvant treatment:1||Neoplasm Metastasis:1||Neoplasm Recurrence:1||Neoplasm invasiveness:1||Neoplasm of uterine cervix:1||Neoplasm staging:1||Neoplasms:1||Nephrectomy:1||Nipplesparing mastectomy:1||Nivolumab:1||Nodenegative:1||Nomogram:1||NonHodgkin:1||Nonaxillary regional lymph node:1||Obesity:1||Olaparib:1||Oligometastasis:1||Ovarian Cancer:1||Ovarian Neoplasms:1||Ovarian function:1||Ovarian transposition:1||Overall survival:1||Pain management:1||Palliative:1||Palliative care:1||Paraaortic recurrence:1||Parametrial involvement:1||Partial mastectomy:1||Particle accelerator:1||Pathologic N1:1||Pathologic complete response:1||Pathology:1||Patientreported outcome:1||Pattern:1||Pattern of failure:1||Patterns of failure:1||Patterns of locoregional recurrence:1||Pectoralis muscle:1||Pelvic radiotherapy:1||Pelvic recurrencepalliative radiation therapy:1||Physical activity:1||Physical therapy:1||Physicians&apos:1||Population dynamics:1||Positioning error values:1||Postmastectomy radiotherapy:1||Postmastectomy radiotherapy:1||Postoperative chemoradiotherapy:1||Postoperative radiation therapy:1||Practice Patterns:1||Primary central nervous system lymphoma:1||Primary central nervous system neoplasms:1||Primary systemic therapy:1||Proctitis:1||Prognostic factors:1||Prognostic group:1||Prone position:1||Proportion:1||Proportional hazards models:1||Prostate canc:1||Prostate neoplasm:1||Prostate neoplasms:1||Protein array analysis:1||Psychological anxiety:1||Quality Assurance:1||Quality assurance:1||RADIOTHERAPY:1||Rad:1||Rad51:1||Radiation:1||Radiation Therapy:1||Radiation dermatitis:1||Radiation dosage:1||Radiation dose hypofractionation:1||Radiation oncology:1||Radiation pneumonitis:1||Radiation protection:1||Radiationinduced neoplasms:1||Radiosurgery:1||Radiotherapy Planning ComputerAssisted:1||Radiotherapy planning:1||Radiotherapyinduced fibrosis:1||Randomized trial:1||Rectum:1||Recurrence pattern:1||Recurrence patterns:1||Regional:1||Regional irradiation:1||Regional lymph node irradiation:1||Reinforcing factor:1||Renal cell carcinoma:1||Resection margin:1||Residual nodal disease:1||Risk Factor:1||SOD mimic:1||SOD mimics:1||Salivary gland cancer:1||Scoring system:1||Sentinel lymph node biopsy:1||Skinsparing mastectomy:1||Small cell carcinoma:1||Smartwatch:1||Spheroid culture:1||Spinal neoplasms:1||Squamous cell carcinom:1||Stage:1||Step counters:1||Stereotactic body radiation therapy:1||Stomach neoplasms:1||Supraclavicular lymph node:1||Supraclavicular lymph nodes:1||Supraclavicular recurrence:1||Survey:1||Surveys and questionnaires:1||Survival Analysis:1||Survival outcomes:1||Synthetic computed tomography:1||Threedimensional conformal radiotherapy:1||Trapezius muscle:1||Triphala:1||Triple Negative Breast Neoplasms:1||Triple negative:1||Triple negative breast cancer:1||Triple negative breast cancer (TNBC):1||Triplenegative breast neoplasms:1||Tubular carcinoma:1||Tumor bed boost:1||Tumor bed recurrence:1||Tumor burden:1||Tumor size:1||Unknown primary:1||Unknown primary neoplasms:1||Upfront surgery:1||Urothelial carcinoma:1||Uterine Cervical Neoplasm:1||Uterine Cervical Neoplasms:1||Uterine carcinosarcoma:1||Vaginal Neoplasms:1||Volume response:1||Waiting time:1||Wearable activity tracker:1||Wholebreast irradiation:1||adaptive radiation therapy:1||adjuvant:1||adverse event:1||anal canal cancer:1||apparent diffusion coefficient:1||artificial intelligence:1||bile duct cancer:1||biological signals:1||bladder distention:1||bowtie filter:1||brachytherapy:1||brain metastasis:1||breast neoplasm:1||breast neoplasms:1||cancer bleeding control:1||cardiovascular event:1||cervix cancer:1||chemoradiotherapy:1||circadian rhythm:1||circumferential extent:1||complication:1||customized bolus:1||cycleGAN:1||data augmentation:1||diffusionweighted imaging:1||doseescalation:1||doseresponse relationship:1||ejection fraction:1||electron beam therapy:1||endocrine therapy:1||epidemiology:1||equipment:1||exercise therapy:1||extracranial disease control:1||facilities:1||gastric cancer:1||half fan mode:1||heart rate variability:1||heartsparing radiotherapy:1||histologic subtype:1||hormonal therapy:1||hormone receptor:1||image synthesis:1||imageguided brachytherapy:1||imaging dose:1||immunebased mechanisms underlying tumor radiosensitization:1||immunohistochemistry:1||intensitymodulated radiation therapy:1||interfractional dose variation:1||interfractional variation:1||intracavitary brachytherapy:1||liver cancer:1||locally advanced cervical cancer:1||lung cancer:1||lymph node involvement:1||machine learning:1||magnetic resonance imaging:1||manganese porphyrin:1||mastectomy:1||megavoltage computed tomography:1||metachronous second primary neoplasm:1||metastatic breast cancer:1||methotrexate:1||molecular subtype:1||molecular subtypes:1||neoadjuvant chemotherapy:1||neoplasm:1||neoplasms, multiple primary:1||pN1:1||palliative radiation therapy:1||paraaortic lymph node recurrence:1||pelvic insufficiency fracture:1||pelvic radiotherapy:1||physiological stress:1||preoperative chemoradiotherapy:1||prognostic factor:1||prognostic factors:1||prostate:1||prostate specific antigen:1||prostatespecific antigen:1||proton therapy:1||quality of life:1||radiation oncology:1||radiationinduced dermatitis:1||radiosensitization:1||radiotherapy dosage:1||radiotherapy infrastructure:1||radiotherapy treatment planning:1||reactive oxygen species:1||rectal cancer:1||regression:1||respiratory irregularity:1||risk assessment:1||salvage:1||singlecell RNA sequencing:1||skin toxicity:1||small bowel:1||squamous cell carcinoma:1||survey:1||survivin:1||synthetic CT:1||threedimensional printing technology:1||total mesorectal excision:1||trastuzumab:1||triplenegative breast neoplasm:1||tumor heterogeneity:1||tumor microenvironment:1||tumor regression:1||unsupervised domain adaptation:1||uterine cervical cancer:1||uterine cervical neoplasm:1||uterine cervical neoplasms:1||uterus mobility:1||weekly CT evaluation:1||보조적 방사선치료:1||소분할 방사선치료:1||양성자치료:1||전립선암:1||>= 5 cm:1||조사선량 증가:1||<:1||13 positive nodes:1||18Ffluorodeoxyglucose:1||3:1||3T MRI:1||= 1 cm Invasive breast cancer:1||ATR inhibitor:1||Adjuvant:1||Adjuvant Radiotherapy:1||Adjuvant radiation therapy:1||Age:1||Age factors:1||Androgen suppression:1||Anthracyclines:1||AntiHER2 targeted therapy:1||Apparent diffusion coefficient:1||Axillary lymph node:1||Axillary lymph node dissection:1||BRCA:1||BRIP1:1||Biological signals:1||Biomarker:1||Biomarkers:1||Bladder cancer:1||Blood oxygenation leveldependent MRI:1||Blood test:1||Body mass index:1||Borderline phyllodes tumor:1||Bowtie filter:1||Breast Cancer:1||Breast cancer recurrence:1||Breast conservation therapy:1||Breast conserving surgery:1||Breast volume changes:1||Breastconserving surgery:1||CBCT:1||CHK1:1||CTbased asymmetry index:1||Carbohydrate Antigen 125:1||Carcinoma:1||Carcinosarcoma:1||Cardiotoxicity:1||Casecontrol studies:1||Central nervous system neoplasms:1||Cervical carcinoma:1||Cervix cancer:1||Cervix uteri:1||Chest wall irradiation:1||Chest wall recurrence risk factor:1||Clinical trial:1||Cluster analysis:1||Colorectal cancer:1||Combined modality therapy:1||Computed Tomography:1||Concurrent chemoradiation:1||Consensus:1||Costs and cost analysis:1||CycleSeg:1||Cyclooxygenase2:1||Dermatitis:1||Diffusionweighted MR imaging:1||Diffusionweighted imaging:1||Distant metastasis:1||Dose calculation parameters:1||Dose escalation:1||Dosimetric variations:1||Dummy run:1||Dynamic contrastenhanced MR imaging:1||Dyslipidemia:1||EMT:1||ERBB2 protein:1||Elective neck irradiation:1||Employment:1||Endocervix:1||Endometrial Neoplasms:1||Endometrial carcinoma:1||Endometrial neoplasms:1||Endoscopy:1||Epidemiology:1||Epithelium:1||Exome:1||Extendedfield RT:1||FDGPET:1||FSH:1||Familial cancer:1||Family history:1||Female:1||Fertility Preservation:1||Fluorodeoxyglucose F18:1||Fractures, compression:1||Full fan mode:1||Fullfan:1||Gastrictype adenocarcinoma:1||Gastroduodenal toxicity:1||Gastrointestinal hemorrhage:1||Genetic counseling:1||Glands:1||HER2:1||HER2overexpressing breast cancer:1||HER2positive breast cancer:1||Half fan:1||Health care costs:1||Health care surveys:1||Health resources:1||Heart rate:1||Helical tomotherapy:1||Hepatocellular carcinoma:1||Human Papillomavirus:1||Hypofractionated radiotherapy:1||Hypofractionation:1||Hypoxia:1||Imageguided brachytherapy:1||Immunotherapy:1||Incidence:1||Incidental findings:1||IntensityModulated:1||Intensitymodulated:1||Intensitymodulated radiation therapy:1||Intensitymodulated radiotherapy:1||Interdisciplinary communication:1||Internal mammary lymph node:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE